Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
Reporting to the VP of BD for Ax, the Head of Ax Business Development will be responsible for driving and executing the Ax GBU’s inorganic growth strategy aligned with the broader corporate objective of expanding Galderma’s global leadership in Ax dermatology.
Working in close partnership with the VP of the Ax GBU, s/he will take the lead on all search, evaluation, due diligence and deal execution activities across all deal types (M&A, co-development/co-promotion, licensing, etc.) and across at all stages of development (from pre-clinical through commercial) with the ultimate end goal of broadening and strengthening the company’s portfolio of aesthetic dermatology products.
S&E:
Due Diligence:
Execution: